# Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 6.0 | nc | (nc-nc) |  | Male | 7 | 4.0 | 174.8 | (70.0-360.2) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 6 | 2.7 | 225.5 | (82.4-490.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 23 | 22.3 | 103.0 | (65.3-154.5) |  | Female | 5 | 2.4 | 208.9 | (67.3-487.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 3.1 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 6.8 | 117.5 | (50.6-231.5) |  |  |  |  |  |  |
| Female | 2 | 5.0 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 27 | 24.8 | 109.1 | (71.9-158.7) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 4 | 1.5 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 7 | 4.0 | 173.5 | (69.5-357.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 6 | 5.3 | 112.8 | (41.2-245.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 11.4 | nc | (nc-nc) |  | Male | 71 | 85.1 | 83.5 | (65.2-105.3) |
| Female | 3 | 9.4 | nc | (nc-nc) |  | Female | 68 | 69.7 | 97.5 | (75.7-123.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

61

# Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 13.3 | 112.9 | (63.1-186.2) |  | Male | 8 | 8.7 | 92.4 | (39.8-182.1) |
| Female | 11 | 4.8 | 230.8 | (115.1-413.0) |  | Female | 14 | 6.8 | 207.3 | (113.2-347.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 7 | 7.6 | 92.2 | (37.0-190.1) |
| Female | 42 | 52.7 | 79.7 | (57.4-107.7) |  | Female | 14 | 6.4 | 217.9 | (119.0-365.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.2 | 97.5 | (35.6-212.1) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 14.6 | 89.1 | (47.4-152.4) |  |  |  |  |  |  |
| Female | 13 | 14.4 | 90.3 | (48.1-154.5) |  | Female | 6 | 4.8 | 125.1 | (45.7-272.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.6 | 138.7 | (44.7-323.7) |  | Male | 5 | 4.5 | 110.2 | (35.5-257.1) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 51 | 48.5 | 105.1 | (78.2-138.2) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 7.3 | 82.5 | (30.1-179.7) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 6 | 4.2 | 143.3 | (52.3-311.9) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 5 | 1.6 | 312.6 | (100.7-729.5) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 5.2 | 95.9 | (30.9-223.8) |  | Male | 2 | 3.3 | nc | (nc-nc) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 7 | 9.5 | 73.6 | (29.5-151.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 14 | 12.2 | 114.3 | (62.4-191.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 33 | 24.4 | 135.2 | (93.0-189.9) |  | Male | 183 | 178.3 | 102.6 | (88.3-118.6) |
| Female | 34 | 25.2 | 135.1 | (93.5-188.7) |  | Female | 197 | 177.5 | 111.0 | (96.0-127.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

62

# Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 11 | 6.1 | 181.3 | (90.4-324.5) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 6.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 24 | 24.2 | 99.1 | (63.5-147.4) |
| Female | 1 | 2.8 | nc | (nc-nc) |  | Female | 21 | 20.1 | 104.5 | (64.7-159.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

63

# Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 12.8 | 109.3 | (59.7-183.4) |  | Male | 4 | 8.6 | nc | (nc-nc) |
| Female | 5 | 4.5 | 112.1 | (36.1-261.7) |  | Female | 4 | 6.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.6 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 5 | 1.9 | 260.9 | (84.1-608.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 9 | 7.7 | 117.2 | (53.5-222.4) |
| Female | 56 | 52.3 | 107.0 | (80.8-139.0) |  | Female | 3 | 6.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 6.3 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 14.8 | 74.2 | (37.0-132.8) |  |  |  |  |  |  |
| Female | 13 | 14.3 | 91.1 | (48.4-155.7) |  | Female | 3 | 4.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 5 | 4.4 | 114.3 | (36.8-266.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 25 | 45.9 | 54.4 | (35.2-80.3) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 7.3 | 96.2 | (38.5-198.2) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 3 | 4.0 | nc | (nc-nc) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 3 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 5.3 | nc | (nc-nc) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 3 | 3.7 | nc | (nc-nc) |  | Female | 10 | 10.4 | 96.0 | (46.0-176.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 13 | 11.4 | 113.7 | (60.5-194.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 22.9 | 96.1 | (60.2-145.6) |  | Male | 136 | 174.5 | 77.9 | (65.4-92.2) |
| Female | 31 | 22.6 | 137.1 | (93.1-194.6) |  | Female | 186 | 173.0 | 107.5 | (92.6-124.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

64

# Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 16.1 | 93.3 | (52.2-153.9) |  | Male | 23 | 8.7 | 264.1 | (167.4-396.4) |
| Female | 11 | 5.5 | 201.5 | (100.4-360.5) |  | Female | 11 | 5.7 | 193.3 | (96.4-345.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 2.0 | 251.5 | (81.0-586.8) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 4 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 5 | 7.7 | 65.2 | (21.0-152.1) |
| Female | 58 | 45.2 | 128.3 | (97.4-165.9) |  | Female | 7 | 6.5 | 107.6 | (43.1-221.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 5.3 | 151.3 | (65.2-298.2) |
| Female | 4 | 1.2 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 15.6 | 109.2 | (63.6-174.9) |  |  |  |  |  |  |
| Female | 14 | 15.6 | 89.6 | (49.0-150.4) |  | Female | 4 | 4.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  | Male | 7 | 5.1 | 137.5 | (55.1-283.3) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 5 | 5.4 | 92.9 | (29.9-216.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 47 | 47.4 | 99.2 | (72.9-132.0) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 6.6 | 91.2 | (33.3-198.5) |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 5 | 4.0 | 125.3 | (40.4-292.4) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 5.4 | 111.3 | (40.6-242.2) |  | Male | 4 | 2.3 | nc | (nc-nc) |
| Female | 2 | 3.7 | nc | (nc-nc) |  | Female | 0 | 5.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 4.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 9 | 10.7 | 84.3 | (38.4-160.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 27.8 | 72.0 | (43.9-111.1) |  | Male | 184 | 182.7 | 100.7 | (86.7-116.4) |
| Female | 28 | 27.3 | 102.7 | (68.2-148.4) |  | Female | 193 | 167.7 | 115.1 | (99.4-132.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

65

# Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 39 | 39.9 | 97.7 | (69.5-133.5) |  | Male | 25 | 25.6 | 97.5 | (63.1-144.0) |
| Female | 16 | 14.9 | 107.7 | (61.5-175.0) |  | Female | 25 | 20.5 | 122.2 | (79.1-180.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 7.3 | 109.8 | (47.3-216.4) |  | Male | 10 | 7.6 | 131.9 | (63.1-242.6) |
| Female | 5 | 6.3 | 79.5 | (25.6-185.5) |  | Female | 7 | 6.3 | 110.9 | (44.4-228.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 24 | 22.6 | 106.4 | (68.1-158.3) |
| Female | 180 | 159.5 | 112.8 | (97.0-130.6) |  | Female | 17 | 19.7 | 86.3 | (50.3-138.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 21 | 18.0 | 116.7 | (72.2-178.4) |
| Female | 5 | 5.4 | 92.6 | (29.8-216.1) |  | Female | 8 | 8.2 | 98.0 | (42.2-193.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 39 | 43.7 | 89.2 | (63.4-121.9) |  |  |  |  |  |  |
| Female | 47 | 45.0 | 104.5 | (76.8-138.9) |  | Female | 16 | 14.5 | 110.3 | (63.0-179.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 10.6 | 84.7 | (38.6-160.7) |  | Male | 12 | 13.5 | 88.6 | (45.7-154.8) |
| Female | 5 | 2.9 | 175.1 | (56.4-408.7) |  | Female | 19 | 14.5 | 131.1 | (78.9-204.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 110 | 141.3 | 77.9 | (64.0-93.9) |
| Female | 5 | 2.4 | 210.2 | (67.7-490.4) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 22 | 21.4 | 103.0 | (64.5-155.9) |  | Male | 4 | 9.3 | nc | (nc-nc) |
| Female | 8 | 12.7 | 62.8 | (27.0-123.7) |  | Female | 6 | 5.6 | 106.3 | (38.8-231.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 5.9 | 102.3 | (37.3-222.6) |  | Male | 7 | 4.6 | 151.7 | (60.8-312.6) |
| Female | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 15.6 | 121.8 | (73.3-190.3) |  | Male | 14 | 9.6 | 146.0 | (79.8-245.0) |
| Female | 25 | 11.6 | 215.1 | (139.2-317.6) |  | Female | 36 | 28.4 | 127.0 | (88.9-175.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 13.4 | 82.4 | (41.1-147.4) |  |  |  |  |  |  |
| Female | 3 | 4.4 | nc | (nc-nc) |  | Female | 42 | 36.2 | 115.9 | (83.5-156.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 71 | 72.4 | 98.0 | (76.6-123.7) |  | Male | 495 | 526.7 | 94.0 | (85.9-102.6) |
| Female | 76 | 77.4 | 98.2 | (77.4-123.0) |  | Female | 596 | 541.5 | 110.1 | (101.4-119.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

66

# Chelsea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 24.2 | 90.9 | (57.0-137.7) |  | Male | 7 | 17.4 | 40.1 | (16.1-82.7) |
| Female | 9 | 8.8 | 102.2 | (46.6-194.0) |  | Female | 7 | 14.9 | 47.0 | (18.8-96.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 5.9 | 117.7 | (47.1-242.4) |  | Male | 4 | 4.8 | nc | (nc-nc) |
| Female | 3 | 4.8 | nc | (nc-nc) |  | Female | 3 | 3.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 17 | 15.6 | 109.3 | (63.6-174.9) |
| Female | 85 | 101.7 | 83.6 | (66.8-103.4) |  | Female | 17 | 12.4 | 136.7 | (79.6-219.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 12.2 | 49.3 | (18.0-107.3) |
| Female | 9 | 4.3 | 208.0 | (94.9-394.8) |  | Female | 7 | 5.1 | 136.3 | (54.6-280.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 31 | 28.3 | 109.7 | (74.5-155.8) |  |  |  |  |  |  |
| Female | 25 | 27.8 | 89.8 | (58.1-132.5) |  | Female | 3 | 9.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 6.6 | 91.3 | (33.3-198.7) |  | Male | 9 | 8.4 | 107.6 | (49.1-204.3) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 16 | 8.6 | 185.5 | (105.9-301.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 3.2 | nc | (nc-nc) |  | Male | 63 | 86.7 | 72.7 | (55.8-93.0) |
| Female | 1 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 14.6 | 82.2 | (42.4-143.6) |  | Male | 10 | 5.9 | 170.5 | (81.6-313.6) |
| Female | 14 | 8.0 | 174.1 | (95.1-292.1) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 3.7 | 136.7 | (44.1-319.1) |  | Male | 2 | 6.5 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 11.2 | 134.3 | (75.1-221.5) |  | Male | 7 | 8.0 | 87.2 | (34.9-179.7) |
| Female | 8 | 8.2 | 97.8 | (42.1-192.7) |  | Female | 40 | 24.2 | 165.6 | (118.3-225.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 17 | 8.6 | 198.0 | (115.3-317.1) |  |  |  |  |  |  |
| Female | 5 | 2.7 | 185.7 | (59.9-433.4) |  | Female | 14 | 22.1 | 63.2 | (34.5-106.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 71 | 43.6 | 163.0 | (127.3-205.6) |  | Male | 344 | 342.7 | 100.4 | (90.1-111.6) |
| Female | 55 | 44.8 | 122.6 | (92.4-159.6) |  | Female | 356 | 348.2 | 102.2 | (91.9-113.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

67

# Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 4.4 | 114.1 | (36.8-266.3) |  | Male | 8 | 2.8 | 281.1 | (121.0-553.9) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 11 | 15.4 | 71.4 | (35.6-127.7) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 4.8 | 124.0 | (45.3-269.9) |  |  |  |  |  |  |
| Female | 2 | 4.2 | nc | (nc-nc) |  | Female | 4 | 1.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 22 | 17.1 | 129.0 | (80.8-195.3) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 5 | 3.6 | 138.4 | (44.6-323.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 8.1 | 184.1 | (103.0-303.7) |  | Male | 76 | 59.9 | 126.9 | (100.0-158.8) |
| Female | 3 | 7.2 | nc | (nc-nc) |  | Female | 38 | 51.3 | 74.0 | (52.4-101.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

68

# Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 4 | 5.9 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 9 | 6.4 | 141.2 | (64.4-268.1) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 3.1 | nc | (nc-nc) |  | Male | 27 | 23.0 | 117.6 | (77.5-171.1) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 13 | 19.2 | 67.9 | (36.1-116.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

69

# Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 2 | 5.7 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 6.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 14 | 21.1 | 66.4 | (36.3-111.4) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 9 | 18.3 | 49.1 | (22.4-93.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

70

# Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 67 | 62.8 | 106.7 | (82.7-135.5) |  | Male | 25 | 39.8 | 62.8 | (40.6-92.7) |
| Female | 17 | 24.8 | 68.4 | (39.8-109.5) |  | Female | 20 | 33.3 | 60.1 | (36.7-92.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 11.3 | 88.2 | (42.2-162.3) |  | Male | 11 | 11.7 | 93.9 | (46.8-168.1) |
| Female | 11 | 10.3 | 106.7 | (53.2-191.0) |  | Female | 8 | 10.4 | 76.8 | (33.1-151.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 31 | 35.2 | 88.0 | (59.8-125.0) |
| Female | 236 | 248.7 | 94.9 | (83.2-107.8) |  | Female | 34 | 32.2 | 105.5 | (73.0-147.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 29 | 27.5 | 105.5 | (70.7-151.5) |
| Female | 8 | 8.4 | 95.3 | (41.0-187.8) |  | Female | 25 | 13.2 | 189.3 | (122.5-279.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 88 | 68.1 | 129.2 | (103.6-159.2) |  |  |  |  |  |  |
| Female | 82 | 74.9 | 109.5 | (87.1-136.0) |  | Female | 30 | 23.2 | 129.4 | (87.3-184.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 16 | 16.4 | 97.7 | (55.8-158.6) |  | Male | 20 | 21.1 | 94.7 | (57.8-146.3) |
| Female | 4 | 4.7 | nc | (nc-nc) |  | Female | 29 | 24.3 | 119.2 | (79.8-171.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 4.8 | 103.8 | (33.5-242.3) |  | Male | 165 | 216.8 | 76.1 | (64.9-88.6) |
| Female | 2 | 4.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 33 | 32.6 | 101.2 | (69.6-142.1) |  | Male | 15 | 14.5 | 103.7 | (58.0-171.0) |
| Female | 23 | 20.4 | 112.6 | (71.4-169.0) |  | Female | 17 | 9.5 | 179.1 | (104.3-286.8) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 9.0 | 88.7 | (38.2-174.7) |  | Male | 12 | 8.0 | 149.6 | (77.2-261.4) |
| Female | 3 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 25 | 24.6 | 101.7 | (65.8-150.1) |  | Male | 8 | 14.7 | 54.2 | (23.4-106.9) |
| Female | 16 | 19.4 | 82.6 | (47.2-134.1) |  | Female | 26 | 44.8 | 58.1 | (37.9-85.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 20.5 | 63.3 | (33.7-108.2) |  |  |  |  |  |  |
| Female | 4 | 7.3 | nc | (nc-nc) |  | Female | 55 | 57.0 | 96.6 | (72.7-125.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 147 | 112.5 | 130.7 | (110.4-153.6) |  | Male | 789 | 817.6 | 96.5 | (89.9-103.5) |
| Female | 141 | 126.0 | 111.9 | (94.2-132.0) |  | Female | 864 | 872.3 | 99.1 | (92.6-105.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

71

# Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 5 | 4.8 | 103.7 | (33.4-242.1) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 1.8 | 337.4 | (123.2-734.4) |  |  |  |  |  |  |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 10 | 5.7 | 175.5 | (84.0-322.8) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  | Male | 26 | 21.2 | 122.7 | (80.1-179.8) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 14 | 16.5 | 85.1 | (46.5-142.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

72

# Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 3 | 8.0 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 2.2 | 277.7 | (101.4-604.4) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 8 | 8.6 | 92.5 | (39.8-182.3) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 3 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 4.5 | 110.7 | (35.7-258.3) |  | Male | 28 | 31.8 | 87.9 | (58.4-127.1) |
| Female | 5 | 3.9 | 128.3 | (41.4-299.5) |  | Female | 25 | 26.7 | 93.5 | (60.5-138.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

73

# Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 13.2 | 120.9 | (69.1-196.3) |  | Male | 6 | 8.9 | 67.5 | (24.6-146.9) |
| Female | 1 | 5.0 | nc | (nc-nc) |  | Female | 6 | 7.5 | 79.8 | (29.1-173.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 4 | 2.3 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 4 | 7.9 | nc | (nc-nc) |
| Female | 63 | 56.3 | 112.0 | (86.0-143.3) |  | Female | 9 | 6.8 | 131.4 | (60.0-249.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.4 | 94.2 | (34.4-205.0) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 15.0 | 93.3 | (51.0-156.5) |  |  |  |  |  |  |
| Female | 18 | 15.7 | 114.9 | (68.1-181.6) |  | Female | 1 | 5.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  | Male | 4 | 4.5 | nc | (nc-nc) |
| Female | 4 | 1.0 | nc | (nc-nc) |  | Female | 7 | 4.9 | 141.8 | (56.8-292.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 52 | 47.9 | 108.5 | (81.0-142.3) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 7.5 | nc | (nc-nc) |  | Male | 5 | 3.1 | 159.0 | (51.2-371.1) |
| Female | 7 | 4.4 | 157.9 | (63.2-325.3) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 5.4 | 91.8 | (29.6-214.3) |  | Male | 2 | 3.6 | nc | (nc-nc) |
| Female | 6 | 4.1 | 144.8 | (52.9-315.1) |  | Female | 7 | 11.1 | 63.3 | (25.4-130.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 14 | 12.7 | 110.5 | (60.3-185.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 31 | 24.0 | 129.2 | (87.8-183.5) |  | Male | 168 | 180.5 | 93.1 | (79.5-108.3) |
| Female | 35 | 26.0 | 134.7 | (93.8-187.4) |  | Female | 202 | 190.3 | 106.2 | (92.0-121.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

74

# Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 9.3 | 54.0 | (17.4-125.9) |  | Male | 9 | 5.9 | 153.7 | (70.1-291.7) |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 11 | 4.4 | 249.4 | (124.3-446.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 5.2 | 96.8 | (31.2-225.8) |
| Female | 37 | 35.3 | 104.9 | (73.9-144.6) |  | Female | 1 | 4.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 10.1 | 148.1 | (82.8-244.3) |  |  |  |  |  |  |
| Female | 7 | 10.3 | 67.9 | (27.2-140.0) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 28 | 32.2 | 86.8 | (57.7-125.5) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 4.9 | 123.1 | (45.0-268.0) |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 5 | 2.8 | 177.0 | (57.0-413.1) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 2 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 8 | 5.9 | 134.5 | (57.9-265.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 8 | 7.9 | 101.1 | (43.5-199.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 16.7 | 47.8 | (20.6-94.3) |  | Male | 103 | 120.8 | 85.3 | (69.6-103.4) |
| Female | 8 | 17.1 | 46.8 | (20.2-92.3) |  | Female | 122 | 120.0 | 101.6 | (84.4-121.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

75

# Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 8 | 7.5 | 106.8 | (46.0-210.4) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 7 | 8.5 | 82.1 | (32.9-169.2) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 5 | 1.8 | 282.5 | (91.0-659.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 4.1 | nc | (nc-nc) |  | Male | 27 | 30.4 | 88.9 | (58.6-129.3) |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 30 | 24.7 | 121.3 | (81.9-173.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

76

# Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 26 | 26.5 | 98.1 | (64.0-143.7) |  | Male | 33 | 16.1 | 204.5 | (140.8-287.3) |
| Female | 6 | 9.6 | 62.7 | (22.9-136.6) |  | Female | 16 | 11.5 | 139.6 | (79.7-226.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 4.3 | 116.2 | (37.4-271.2) |  | Male | 2 | 4.8 | nc | (nc-nc) |
| Female | 5 | 3.6 | 139.3 | (44.9-325.0) |  | Female | 3 | 4.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 12 | 14.3 | 83.8 | (43.2-146.3) |
| Female | 107 | 91.0 | 117.6 | (96.4-142.1) |  | Female | 12 | 12.0 | 100.0 | (51.6-174.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 10.9 | 73.5 | (31.7-144.8) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 1 | 4.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 28.3 | 67.1 | (40.4-104.7) |  |  |  |  |  |  |
| Female | 33 | 28.9 | 114.4 | (78.7-160.6) |  | Female | 11 | 8.5 | 130.1 | (64.9-232.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 6.6 | nc | (nc-nc) |  | Male | 14 | 8.7 | 160.1 | (87.5-268.7) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 7 | 9.4 | 74.2 | (29.7-152.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 90 | 85.3 | 105.5 | (84.9-129.7) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 12.9 | 115.9 | (64.8-191.3) |  | Male | 0 | 6.0 | nc | (nc-nc) |
| Female | 7 | 7.5 | 93.4 | (37.4-192.5) |  | Female | 0 | 3.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 3.6 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 9.9 | 101.0 | (48.3-185.7) |  | Male | 4 | 5.5 | nc | (nc-nc) |
| Female | 5 | 7.1 | 70.3 | (22.7-164.1) |  | Female | 12 | 13.9 | 86.4 | (44.6-151.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 8.2 | 60.8 | (19.6-142.0) |  |  |  |  |  |  |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 24 | 20.8 | 115.3 | (73.9-171.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 46.4 | 40.9 | (24.6-63.9) |  | Male | 299 | 330.1 | 90.6 | (80.6-101.4) |
| Female | 24 | 47.1 | 51.0 | (32.7-75.9) |  | Female | 310 | 320.2 | 96.8 | (86.3-108.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

77

# Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 2 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 10 | 9.1 | 110.0 | (52.7-202.4) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 8 | 9.6 | 83.3 | (35.8-164.1) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 4.3 | nc | (nc-nc) |  | Male | 32 | 32.5 | 98.3 | (67.2-138.8) |
| Female | 1 | 3.8 | nc | (nc-nc) |  | Female | 23 | 28.7 | 80.3 | (50.9-120.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

78

# Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 3 | 0.7 | nc | (nc-nc) |
| Female | 9 | 4.2 | 213.0 | (97.2-404.3) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 4.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 5 | 1.0 | 502.5 | (161.9-1172.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 13 | 16.1 | 80.5 | (42.8-137.7) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 24 | 13.8 | 174.1 | (111.5-259.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

79

# Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 9.1 | 120.8 | (60.2-216.2) |  | Male | 11 | 5.6 | 197.0 | (98.2-352.5) |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 3 | 4.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 4.9 | nc | (nc-nc) |
| Female | 27 | 33.4 | 80.8 | (53.2-117.5) |  | Female | 4 | 4.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 3.8 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 9.7 | 123.5 | (63.7-215.7) |  |  |  |  |  |  |
| Female | 11 | 10.2 | 108.2 | (53.9-193.5) |  | Female | 4 | 3.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 3.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 32 | 30.2 | 106.0 | (72.5-149.6) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 4.5 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.5 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 2 | 5.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 9 | 7.6 | 117.8 | (53.7-223.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 16.1 | 86.8 | (47.4-145.7) |  | Male | 102 | 115.0 | 88.7 | (72.3-107.7) |
| Female | 22 | 17.0 | 129.5 | (81.1-196.0) |  | Female | 104 | 116.7 | 89.1 | (72.8-108.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

80

# Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 39 | 33.9 | 114.9 | (81.7-157.1) |  | Male | 23 | 21.0 | 109.5 | (69.4-164.2) |
| Female | 9 | 13.4 | 67.2 | (30.7-127.6) |  | Female | 17 | 17.3 | 98.1 | (57.1-157.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 5.7 | 209.0 | (107.9-365.2) |  | Male | 3 | 6.3 | nc | (nc-nc) |
| Female | 4 | 5.3 | nc | (nc-nc) |  | Female | 2 | 5.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 13 | 18.6 | 69.9 | (37.2-119.6) |
| Female | 143 | 132.9 | 107.6 | (90.7-126.7) |  | Female | 27 | 17.2 | 157.2 | (103.5-228.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 14.3 | 98.1 | (53.6-164.7) |
| Female | 4 | 4.4 | nc | (nc-nc) |  | Female | 6 | 7.0 | 85.3 | (31.2-185.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 29 | 36.4 | 79.6 | (53.3-114.4) |  |  |  |  |  |  |
| Female | 40 | 40.8 | 98.1 | (70.1-133.6) |  | Female | 13 | 12.3 | 106.0 | (56.4-181.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 8.6 | 127.7 | (63.6-228.4) |  | Male | 13 | 11.3 | 115.5 | (61.4-197.4) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 12 | 13.2 | 91.1 | (47.0-159.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 140 | 111.7 | 125.4 | (105.5-147.9) |
| Female | 4 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 22 | 17.0 | 129.4 | (81.1-195.9) |  | Male | 5 | 7.7 | 64.5 | (20.8-150.6) |
| Female | 9 | 10.8 | 83.0 | (37.9-157.6) |  | Female | 7 | 5.2 | 135.3 | (54.2-278.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 4.7 | nc | (nc-nc) |  | Male | 9 | 3.5 | 257.3 | (117.4-488.5) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 12.9 | 139.6 | (82.7-220.6) |  | Male | 10 | 7.4 | 135.1 | (64.7-248.5) |
| Female | 16 | 10.3 | 156.0 | (89.1-253.3) |  | Female | 19 | 22.8 | 83.4 | (50.2-130.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 10.8 | 111.6 | (57.6-194.9) |  |  |  |  |  |  |
| Female | 5 | 3.9 | 129.2 | (41.6-301.5) |  | Female | 34 | 29.9 | 113.7 | (78.8-159.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 66 | 60.2 | 109.7 | (84.8-139.5) |  | Male | 477 | 429.4 | 111.1 | (101.3-121.5) |
| Female | 58 | 67.0 | 86.6 | (65.7-111.9) |  | Female | 467 | 464.1 | 100.6 | (91.7-110.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

81

# Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 54 | 39.7 | 136.2 | (102.3-177.7) |  | Male | 21 | 24.9 | 84.5 | (52.3-129.1) |
| Female | 19 | 14.6 | 130.0 | (78.2-203.0) |  | Female | 16 | 19.3 | 82.8 | (47.3-134.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 7.0 | 113.8 | (49.0-224.3) |  | Male | 5 | 7.3 | 68.1 | (21.9-158.9) |
| Female | 6 | 6.0 | 99.9 | (36.5-217.5) |  | Female | 6 | 6.1 | 98.0 | (35.8-213.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 21 | 22.2 | 94.6 | (58.5-144.6) |
| Female | 120 | 146.3 | 82.0 | (68.0-98.1) |  | Female | 23 | 18.9 | 121.4 | (76.9-182.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 17.1 | 99.2 | (57.8-158.8) |
| Female | 6 | 4.8 | 125.1 | (45.7-272.3) |  | Female | 10 | 7.8 | 128.7 | (61.6-236.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 39 | 42.7 | 91.4 | (65.0-125.0) |  |  |  |  |  |  |
| Female | 51 | 44.2 | 115.4 | (85.9-151.7) |  | Female | 11 | 13.6 | 80.6 | (40.2-144.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 10.3 | 106.8 | (53.2-191.1) |  | Male | 13 | 13.3 | 97.8 | (52.0-167.3) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 7 | 14.4 | 48.6 | (19.5-100.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 179 | 136.2 | 131.4 | (112.8-152.1) |
| Female | 2 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 27 | 20.3 | 133.3 | (87.8-193.9) |  | Male | 13 | 9.1 | 143.1 | (76.1-244.8) |
| Female | 16 | 11.9 | 134.3 | (76.7-218.2) |  | Female | 8 | 5.6 | 142.4 | (61.3-280.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 5.6 | nc | (nc-nc) |  | Male | 5 | 5.2 | 95.6 | (30.8-223.0) |
| Female | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 15.5 | 122.8 | (73.9-191.8) |  | Male | 12 | 9.2 | 130.2 | (67.2-227.5) |
| Female | 9 | 11.3 | 79.8 | (36.4-151.5) |  | Female | 34 | 25.7 | 132.1 | (91.5-184.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 12.8 | 62.7 | (27.0-123.6) |  |  |  |  |  |  |
| Female | 2 | 4.3 | nc | (nc-nc) |  | Female | 34 | 33.5 | 101.6 | (70.4-142.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 74 | 70.5 | 105.0 | (82.4-131.8) |  | Male | 572 | 513.6 | 111.4 | (102.4-120.9) |
| Female | 43 | 73.6 | 58.4 | (42.3-78.7) |  | Female | 467 | 511.5 | 91.3 | (83.2-100.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

82

# Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 37 | 32.7 | 113.0 | (79.6-155.8) |  | Male | 21 | 19.9 | 105.3 | (65.2-161.0) |
| Female | 9 | 12.7 | 70.7 | (32.3-134.2) |  | Female | 23 | 15.9 | 144.3 | (91.4-216.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 5.4 | 128.7 | (51.6-265.3) |  | Male | 5 | 5.9 | 84.5 | (27.2-197.2) |
| Female | 4 | 4.9 | nc | (nc-nc) |  | Female | 1 | 5.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 20 | 17.8 | 112.7 | (68.8-174.0) |
| Female | 132 | 120.9 | 109.2 | (91.3-129.4) |  | Female | 14 | 16.0 | 87.4 | (47.7-146.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 13.3 | 105.6 | (57.7-177.2) |
| Female | 6 | 3.9 | 152.1 | (55.5-331.1) |  | Female | 4 | 6.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 32 | 34.8 | 91.9 | (62.8-129.7) |  |  |  |  |  |  |
| Female | 34 | 38.6 | 88.0 | (61.0-123.0) |  | Female | 13 | 11.2 | 115.8 | (61.6-198.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 8.1 | 74.1 | (27.1-161.4) |  | Male | 13 | 10.7 | 120.9 | (64.3-206.8) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 16 | 12.6 | 127.4 | (72.8-207.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 87 | 103.3 | 84.2 | (67.5-103.9) |
| Female | 3 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 15.9 | 82.0 | (43.6-140.3) |  | Male | 8 | 7.4 | 108.2 | (46.6-213.1) |
| Female | 12 | 10.0 | 119.9 | (61.9-209.5) |  | Female | 6 | 4.9 | 121.4 | (44.3-264.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 4.4 | nc | (nc-nc) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 12.4 | 72.4 | (33.0-137.4) |  | Male | 6 | 6.9 | 86.5 | (31.6-188.3) |
| Female | 5 | 9.7 | 51.7 | (16.7-120.6) |  | Female | 30 | 20.4 | 147.0 | (99.1-209.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 10.0 | 100.2 | (48.0-184.4) |  |  |  |  |  |  |
| Female | 6 | 3.6 | 166.7 | (60.9-362.8) |  | Female | 26 | 27.0 | 96.4 | (63.0-141.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 58 | 56.9 | 102.0 | (77.5-131.9) |  | Male | 386 | 405.6 | 95.2 | (85.9-105.2) |
| Female | 72 | 62.4 | 115.4 | (90.3-145.4) |  | Female | 444 | 429.0 | 103.5 | (94.1-113.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

83

# Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 6.3 | nc | (nc-nc) |  | Male | 5 | 4.1 | 121.6 | (39.2-283.7) |
| Female | 4 | 2.2 | nc | (nc-nc) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 22 | 25.0 | 88.1 | (55.2-133.4) |  | Female | 4 | 3.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 7.0 | 86.0 | (31.4-187.1) |  |  |  |  |  |  |
| Female | 2 | 6.7 | nc | (nc-nc) |  | Female | 0 | 2.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 2.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 23 | 24.3 | 94.7 | (60.0-142.1) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 3.5 | 199.5 | (79.9-411.1) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 3 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 5.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 11.7 | nc | (nc-nc) |  | Male | 64 | 86.2 | 74.2 | (57.1-94.8) |
| Female | 4 | 11.7 | nc | (nc-nc) |  | Female | 57 | 83.2 | 68.5 | (51.9-88.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

84

# Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 32 | 31.1 | 102.8 | (70.3-145.1) |  | Male | 31 | 17.4 | 178.0 | (120.9-252.7) |
| Female | 11 | 11.1 | 98.9 | (49.3-176.9) |  | Female | 26 | 12.3 | 211.3 | (138.0-309.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 4.1 | nc | (nc-nc) |  | Male | 5 | 5.4 | 92.5 | (29.8-215.9) |
| Female | 2 | 3.8 | nc | (nc-nc) |  | Female | 2 | 4.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 17 | 15.3 | 111.3 | (64.8-178.1) |
| Female | 124 | 98.2 | 126.3 | (105.1-150.6) |  | Female | 13 | 13.6 | 95.6 | (50.9-163.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 19 | 10.9 | 174.0 | (104.7-271.7) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 4 | 5.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 32 | 30.7 | 104.1 | (71.2-147.0) |  |  |  |  |  |  |
| Female | 32 | 31.8 | 100.6 | (68.8-142.0) |  | Female | 10 | 9.2 | 108.3 | (51.8-199.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 7.5 | 106.8 | (46.0-210.5) |  | Male | 13 | 10.0 | 130.1 | (69.2-222.5) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 10 | 10.9 | 92.0 | (44.0-169.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 121 | 96.5 | 125.3 | (104.0-149.8) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 13.5 | 66.6 | (30.4-126.4) |  | Male | 2 | 6.7 | nc | (nc-nc) |
| Female | 8 | 8.5 | 94.2 | (40.6-185.7) |  | Female | 4 | 4.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 4.0 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 10.7 | 122.0 | (64.9-208.7) |  | Male | 1 | 4.9 | nc | (nc-nc) |
| Female | 7 | 7.7 | 90.4 | (36.2-186.3) |  | Female | 17 | 13.3 | 128.3 | (74.7-205.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 8.6 | 115.6 | (55.3-212.6) |  |  |  |  |  |  |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 26 | 23.4 | 111.3 | (72.7-163.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 51 | 54.9 | 93.0 | (69.2-122.2) |  | Male | 407 | 365.4 | 111.4 | (100.8-122.7) |
| Female | 55 | 57.0 | 96.4 | (72.6-125.5) |  | Female | 396 | 355.7 | 111.3 | (100.6-122.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

85

# Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 7.2 | 97.1 | (38.9-200.1) |  | Male | 6 | 4.8 | 124.8 | (45.6-271.6) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 5 | 3.8 | 133.0 | (42.9-310.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 4.3 | nc | (nc-nc) |
| Female | 16 | 29.2 | 54.7 | (31.2-88.8) |  | Female | 0 | 3.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 8.2 | 158.2 | (84.1-270.5) |  |  |  |  |  |  |
| Female | 4 | 7.8 | nc | (nc-nc) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 5 | 2.5 | 199.1 | (64.2-464.6) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 30 | 27.4 | 109.5 | (73.8-156.3) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 4.1 | 144.7 | (52.8-314.9) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 4 | 2.3 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 3.0 | nc | (nc-nc) |  | Male | 4 | 1.9 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 5 | 5.6 | 88.7 | (28.6-207.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 6 | 6.6 | 91.4 | (33.4-198.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 13.1 | 68.6 | (31.3-130.1) |  | Male | 98 | 99.6 | 98.3 | (79.8-119.9) |
| Female | 12 | 13.1 | 91.4 | (47.2-159.7) |  | Female | 74 | 96.7 | 76.6 | (60.1-96.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

86

# Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 6.2 | 144.4 | (65.9-274.0) |  | Male | 6 | 4.8 | 125.6 | (45.9-273.4) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 6 | 3.9 | 155.3 | (56.7-338.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 29 | 29.7 | 97.7 | (65.4-140.3) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 7.9 | 76.1 | (27.8-165.6) |  |  |  |  |  |  |
| Female | 5 | 6.8 | 73.2 | (23.6-170.9) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 1.9 | 258.4 | (83.3-603.1) |  | Male | 4 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 24 | 27.3 | 87.9 | (56.3-130.8) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 4.4 | 137.9 | (50.3-300.1) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 4 | 1.9 | nc | (nc-nc) |  | Female | 5 | 6.7 | 75.1 | (24.2-175.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 9 | 6.5 | 138.3 | (63.1-262.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 12.0 | 91.9 | (45.8-164.5) |  | Male | 102 | 97.1 | 105.1 | (85.7-127.5) |
| Female | 13 | 11.3 | 114.9 | (61.1-196.6) |  | Female | 91 | 93.0 | 97.8 | (78.8-120.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

87

# Dover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 6.6 | nc | (nc-nc) |  | Male | 10 | 4.3 | 230.2 | (110.2-423.3) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 8 | 3.8 | 209.3 | (90.1-412.5) |
| Female | 28 | 24.4 | 114.6 | (76.1-165.7) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 7.4 | 67.4 | (21.7-157.4) |  |  |  |  |  |  |
| Female | 4 | 6.0 | nc | (nc-nc) |  | Female | 0 | 2.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 24 | 26.0 | 92.5 | (59.2-137.6) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 3.8 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 4 | 1.6 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 5 | 4.4 | 113.6 | (36.6-265.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 5.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 12.4 | 40.2 | (13.0-93.8) |  | Male | 84 | 91.6 | 91.7 | (73.1-113.5) |
| Female | 6 | 10.7 | 55.8 | (20.4-121.5) |  | Female | 66 | 78.2 | 84.4 | (65.3-107.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

88

# Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 39 | 29.0 | 134.4 | (95.5-183.7) |  | Male | 11 | 19.5 | 56.4 | (28.1-101.0) |
| Female | 18 | 10.5 | 171.3 | (101.5-270.8) |  | Female | 17 | 16.0 | 106.3 | (61.9-170.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 5.8 | 137.0 | (59.0-270.0) |  | Male | 6 | 5.6 | 106.2 | (38.8-231.2) |
| Female | 6 | 4.9 | 121.9 | (44.5-265.3) |  | Female | 4 | 4.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 18 | 17.2 | 104.4 | (61.9-165.0) |
| Female | 133 | 121.8 | 109.2 | (91.4-129.4) |  | Female | 8 | 14.5 | 55.3 | (23.8-109.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 14.1 | 64.0 | (29.2-121.5) |
| Female | 6 | 4.4 | 134.9 | (49.3-293.6) |  | Female | 8 | 6.1 | 131.3 | (56.5-258.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 40 | 32.8 | 121.9 | (87.1-166.0) |  |  |  |  |  |  |
| Female | 44 | 32.4 | 135.7 | (98.6-182.2) |  | Female | 14 | 11.0 | 127.3 | (69.5-213.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 8.0 | 150.4 | (77.6-262.7) |  | Male | 5 | 10.0 | 50.0 | (16.1-116.6) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 13 | 10.2 | 127.9 | (68.0-218.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 98 | 107.3 | 91.3 | (74.2-111.3) |
| Female | 3 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 16.5 | 120.9 | (73.8-186.8) |  | Male | 4 | 6.9 | nc | (nc-nc) |
| Female | 8 | 9.5 | 84.1 | (36.2-165.7) |  | Female | 5 | 4.0 | 124.0 | (40.0-289.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 4.4 | nc | (nc-nc) |  | Male | 1 | 4.4 | nc | (nc-nc) |
| Female | 2 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 22 | 11.9 | 184.9 | (115.8-279.9) |  | Male | 6 | 7.9 | 75.9 | (27.7-165.3) |
| Female | 10 | 8.7 | 115.3 | (55.2-212.0) |  | Female | 28 | 24.0 | 116.6 | (77.5-168.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 10.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 3.3 | nc | (nc-nc) |  | Female | 18 | 27.5 | 65.4 | (38.8-103.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 57 | 53.0 | 107.5 | (81.4-139.3) |  | Male | 401 | 398.2 | 100.7 | (91.1-111.0) |
| Female | 73 | 55.6 | 131.4 | (103.0-165.2) |  | Female | 459 | 405.8 | 113.1 | (103.0-123.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

89

# Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 11.0 | 72.8 | (31.3-143.4) |  | Male | 4 | 7.3 | nc | (nc-nc) |
| Female | 4 | 3.7 | nc | (nc-nc) |  | Female | 4 | 5.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 3 | 6.5 | nc | (nc-nc) |
| Female | 36 | 43.5 | 82.7 | (57.9-114.5) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 5.3 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 12.4 | 113.2 | (61.8-189.9) |  |  |  |  |  |  |
| Female | 12 | 11.6 | 103.1 | (53.2-180.2) |  | Female | 8 | 3.9 | 202.7 | (87.3-399.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  | Male | 5 | 3.8 | 132.8 | (42.8-309.9) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 32 | 40.0 | 80.0 | (54.7-112.9) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 6.2 | 97.3 | (35.5-211.7) |  | Male | 4 | 2.6 | nc | (nc-nc) |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.7 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 4.5 | 198.6 | (90.6-377.1) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 12 | 8.7 | 138.0 | (71.2-241.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 16 | 9.8 | 162.8 | (93.0-264.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 19.9 | 140.7 | (93.5-203.4) |  | Male | 146 | 149.8 | 97.4 | (82.3-114.6) |
| Female | 23 | 19.5 | 117.9 | (74.7-176.9) |  | Female | 147 | 145.1 | 101.3 | (85.6-119.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

90

# Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 3 | 0.9 | nc | (nc-nc) |  | Female | 3 | 1.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 16 | 12.9 | 124.0 | (70.8-201.3) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 3.4 | 205.5 | (82.3-423.5) |  |  |  |  |  |  |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 8 | 12.2 | 65.6 | (28.2-129.2) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 1.9 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 2 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 5.4 | nc | (nc-nc) |  | Male | 42 | 42.3 | 99.2 | (71.5-134.1) |
| Female | 6 | 5.0 | 119.9 | (43.8-260.9) |  | Female | 41 | 39.7 | 103.3 | (74.1-140.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

91

# Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 24 | 18.5 | 129.6 | (83.0-192.8) |  | Male | 26 | 11.7 | 221.6 | (144.7-324.7) |
| Female | 2 | 6.7 | nc | (nc-nc) |  | Female | 14 | 9.0 | 155.2 | (84.8-260.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.3 | 150.1 | (48.4-350.2) |  | Male | 5 | 3.5 | 141.8 | (45.7-330.9) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 11 | 10.4 | 105.8 | (52.7-189.3) |
| Female | 78 | 72.4 | 107.8 | (85.2-134.5) |  | Female | 3 | 8.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 8.5 | 58.6 | (18.9-136.7) |
| Female | 0 | 2.4 | nc | (nc-nc) |  | Female | 4 | 3.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 20.3 | 54.1 | (27.0-96.8) |  |  |  |  |  |  |
| Female | 12 | 20.4 | 58.8 | (30.3-102.7) |  | Female | 9 | 6.6 | 137.0 | (62.5-260.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 5.0 | 158.6 | (68.3-312.6) |  | Male | 4 | 6.4 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 5 | 6.6 | 76.1 | (24.5-177.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 1.2 | nc | (nc-nc) |  | Male | 78 | 68.8 | 113.4 | (89.7-141.6) |
| Female | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 10.0 | 120.3 | (62.1-210.1) |  | Male | 0 | 4.3 | nc | (nc-nc) |
| Female | 3 | 5.7 | nc | (nc-nc) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.8 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 7.2 | 83.5 | (30.5-181.7) |  | Male | 0 | 4.3 | nc | (nc-nc) |
| Female | 5 | 5.3 | 95.1 | (30.6-221.9) |  | Female | 15 | 12.2 | 122.6 | (68.6-202.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 6.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 9 | 16.6 | 54.1 | (24.7-102.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 23 | 33.6 | 68.4 | (43.3-102.6) |  | Male | 247 | 247.1 | 100.0 | (87.9-113.2) |
| Female | 18 | 34.1 | 52.9 | (31.3-83.5) |  | Female | 207 | 243.5 | 85.0 | (73.8-97.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

92

# East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 13.5 | 111.0 | (62.1-183.1) |  | Male | 11 | 9.2 | 119.5 | (59.6-213.9) |
| Female | 8 | 4.9 | 163.6 | (70.4-322.3) |  | Female | 11 | 7.4 | 147.9 | (73.7-264.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 0 | 2.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 8 | 8.1 | 99.1 | (42.7-195.2) |
| Female | 47 | 57.7 | 81.5 | (59.9-108.3) |  | Female | 11 | 6.8 | 161.5 | (80.5-289.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 6.8 | 103.2 | (41.3-212.6) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 15.4 | 90.9 | (49.6-152.4) |  |  |  |  |  |  |
| Female | 13 | 15.0 | 86.7 | (46.1-148.2) |  | Female | 5 | 5.2 | 96.3 | (31.0-224.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.8 | 130.6 | (42.1-304.7) |  | Male | 2 | 4.7 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 7 | 4.7 | 147.8 | (59.2-304.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 47 | 52.7 | 89.2 | (65.6-118.7) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 8.0 | 138.0 | (68.8-247.0) |  | Male | 3 | 3.2 | nc | (nc-nc) |
| Female | 3 | 4.5 | nc | (nc-nc) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 5.6 | nc | (nc-nc) |  | Male | 6 | 3.8 | 159.5 | (58.3-347.3) |
| Female | 3 | 4.0 | nc | (nc-nc) |  | Female | 13 | 11.1 | 116.8 | (62.1-199.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 15 | 13.2 | 113.5 | (63.5-187.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 25.2 | 127.0 | (86.8-179.2) |  | Male | 189 | 189.9 | 99.5 | (85.9-114.8) |
| Female | 30 | 26.2 | 114.4 | (77.2-163.3) |  | Female | 196 | 190.8 | 102.7 | (88.8-118.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

93

# East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 2.5 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 2 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 8 | 9.0 | 89.4 | (38.5-176.1) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 2.8 | 178.3 | (57.5-416.1) |  |  |  |  |  |  |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 8 | 9.7 | 82.7 | (35.6-163.0) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 4.6 | nc | (nc-nc) |  | Male | 30 | 34.4 | 87.1 | (58.8-124.3) |
| Female | 4 | 4.1 | nc | (nc-nc) |  | Female | 30 | 29.8 | 100.8 | (68.0-144.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

94

# East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 22.0 | 99.8 | (62.5-151.1) |  | Male | 18 | 13.1 | 137.1 | (81.2-216.6) |
| Female | 4 | 8.9 | nc | (nc-nc) |  | Female | 7 | 10.6 | 66.1 | (26.5-136.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 0 | 3.9 | nc | (nc-nc) |
| Female | 0 | 3.3 | nc | (nc-nc) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 11 | 11.8 | 93.6 | (46.7-167.5) |
| Female | 73 | 81.0 | 90.1 | (70.6-113.3) |  | Female | 9 | 11.0 | 81.9 | (37.4-155.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 8.7 | 80.3 | (32.2-165.5) |
| Female | 0 | 2.6 | nc | (nc-nc) |  | Female | 5 | 4.4 | 113.2 | (36.5-264.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 23.3 | 64.2 | (35.9-106.0) |  |  |  |  |  |  |
| Female | 20 | 27.1 | 73.9 | (45.1-114.1) |  | Female | 8 | 7.6 | 105.7 | (45.5-208.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 5.4 | nc | (nc-nc) |  | Male | 5 | 7.2 | 69.5 | (22.4-162.3) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 13 | 8.8 | 147.1 | (78.3-251.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 66 | 68.2 | 96.7 | (74.8-123.1) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 10.4 | 125.2 | (66.6-214.1) |  | Male | 6 | 5.0 | 121.1 | (44.2-263.7) |
| Female | 11 | 6.7 | 163.0 | (81.3-291.7) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 8.2 | 85.0 | (34.0-175.1) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 2 | 6.7 | nc | (nc-nc) |  | Female | 9 | 13.0 | 69.4 | (31.7-131.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 12 | 17.9 | 67.1 | (34.6-117.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 38.0 | 89.5 | (62.0-125.1) |  | Male | 241 | 268.8 | 89.7 | (78.7-101.7) |
| Female | 44 | 42.4 | 103.7 | (75.4-139.2) |  | Female | 254 | 290.9 | 87.3 | (76.9-98.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

95

# Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 11.9 | 42.2 | (13.6-98.4) |  | Male | 8 | 6.6 | 121.8 | (52.4-239.9) |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 16 | 4.3 | 375.5 | (214.5-609.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 3 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 2 | 5.8 | nc | (nc-nc) |
| Female | 46 | 34.5 | 133.2 | (97.5-177.7) |  | Female | 8 | 4.7 | 171.5 | (73.8-337.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 11.6 | 60.1 | (24.1-123.9) |  |  |  |  |  |  |
| Female | 11 | 10.7 | 102.6 | (51.1-183.5) |  | Female | 5 | 3.2 | 155.4 | (50.1-362.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 2.8 | nc | (nc-nc) |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 6 | 3.7 | 164.2 | (60.0-357.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 41 | 36.6 | 112.0 | (80.3-151.9) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 5.1 | nc | (nc-nc) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 4.0 | 223.9 | (102.2-425.1) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 2 | 4.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 7 | 8.3 | 84.0 | (33.7-173.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 20.8 | 105.9 | (66.4-160.4) |  | Male | 124 | 138.3 | 89.6 | (74.6-106.9) |
| Female | 17 | 19.6 | 86.5 | (50.4-138.6) |  | Female | 145 | 123.1 | 117.8 | (99.4-138.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

96

# Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 18.3 | 65.5 | (33.8-114.4) |  | Male | 6 | 12.0 | 50.2 | (18.3-109.3) |
| Female | 3 | 6.9 | nc | (nc-nc) |  | Female | 7 | 9.9 | 70.8 | (28.3-145.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 6 | 10.6 | 56.8 | (20.7-123.6) |
| Female | 70 | 74.9 | 93.5 | (72.9-118.1) |  | Female | 8 | 9.2 | 86.7 | (37.3-170.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 8.7 | 104.0 | (47.5-197.5) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 8 | 3.9 | 206.6 | (89.0-407.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 33 | 20.4 | 161.7 | (111.3-227.1) |  |  |  |  |  |  |
| Female | 29 | 21.1 | 137.3 | (92.0-197.3) |  | Female | 2 | 6.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 5.0 | 100.6 | (32.4-234.8) |  | Male | 4 | 6.3 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 7 | 6.7 | 104.1 | (41.7-214.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 67 | 66.8 | 100.2 | (77.7-127.3) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 10.0 | 79.9 | (34.4-157.4) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 8 | 5.9 | 135.0 | (58.1-266.0) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 7.2 | 96.7 | (38.7-199.3) |  | Male | 1 | 4.6 | nc | (nc-nc) |
| Female | 5 | 5.4 | 91.8 | (29.6-214.2) |  | Female | 10 | 14.1 | 71.1 | (34.1-130.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 14 | 17.3 | 81.0 | (44.2-135.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 31 | 32.9 | 94.2 | (64.0-133.7) |  | Male | 224 | 246.3 | 91.0 | (79.4-103.7) |
| Female | 32 | 35.2 | 90.9 | (62.2-128.4) |  | Female | 235 | 254.5 | 92.4 | (80.9-104.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

97

# Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 22.5 | 97.7 | (61.2-147.9) |  | Male | 19 | 15.1 | 125.6 | (75.6-196.2) |
| Female | 9 | 7.6 | 118.0 | (53.9-224.1) |  | Female | 17 | 11.9 | 142.3 | (82.8-227.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 4.5 | 155.5 | (62.3-320.4) |  | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 6 | 3.8 | 159.3 | (58.2-346.7) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 0.7 | nc | (nc-nc) |  | Male | 10 | 13.3 | 74.9 | (35.9-137.8) |
| Female | 117 | 92.1 | 127.1 | (105.1-152.3) |  | Female | 14 | 10.7 | 130.3 | (71.2-218.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 11.1 | 80.8 | (36.9-153.4) |
| Female | 1 | 3.3 | nc | (nc-nc) |  | Female | 3 | 4.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 25.4 | 82.6 | (51.1-126.2) |  |  |  |  |  |  |
| Female | 34 | 23.6 | 144.2 | (99.9-201.5) |  | Female | 8 | 8.3 | 95.9 | (41.3-189.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 6.3 | 110.5 | (44.3-227.7) |  | Male | 6 | 7.9 | 76.4 | (27.9-166.3) |
| Female | 3 | 1.5 | nc | (nc-nc) |  | Female | 7 | 7.4 | 94.9 | (38.0-195.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 74 | 87.0 | 85.1 | (66.8-106.8) |
| Female | 2 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 13.0 | 115.3 | (64.5-190.2) |  | Male | 5 | 5.4 | 92.9 | (29.9-216.7) |
| Female | 8 | 7.1 | 113.0 | (48.7-222.7) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 5 | 3.1 | 159.7 | (51.5-372.7) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 9.2 | 152.5 | (83.3-256.0) |  | Male | 10 | 6.1 | 164.5 | (78.7-302.5) |
| Female | 7 | 6.4 | 109.2 | (43.8-225.0) |  | Female | 24 | 18.2 | 132.1 | (84.6-196.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 8.1 | 86.1 | (34.5-177.5) |  |  |  |  |  |  |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 18 | 21.1 | 85.1 | (50.4-134.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 37 | 41.8 | 88.5 | (62.3-122.0) |  | Male | 303 | 313.8 | 96.6 | (86.0-108.1) |
| Female | 39 | 40.9 | 95.4 | (67.8-130.4) |  | Female | 354 | 302.9 | 116.9 | (105.0-129.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

98

# Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 5.4 | 130.5 | (52.3-268.9) |  | Male | 11 | 3.5 | 315.1 | (157.1-563.8) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 4 | 2.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 18 | 18.5 | 97.6 | (57.8-154.2) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 3 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 5.9 | 84.9 | (27.4-198.2) |  |  |  |  |  |  |
| Female | 4 | 4.8 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 29 | 20.4 | 142.4 | (95.3-204.5) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 5 | 3.3 | 149.8 | (48.3-349.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 5 | 4.4 | 113.8 | (36.7-265.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 9.9 | 80.8 | (34.8-159.2) |  | Male | 80 | 72.8 | 109.9 | (87.1-136.7) |
| Female | 11 | 8.7 | 126.5 | (63.1-226.3) |  | Female | 66 | 61.2 | 107.9 | (83.4-137.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

99

# Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 2.3 | nc | (nc-nc) |  | Male | 4 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 3 | 7.7 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 2.4 | 210.4 | (67.8-491.0) |  |  |  |  |  |  |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 6 | 8.3 | 72.0 | (26.3-156.7) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 4.3 | nc | (nc-nc) |  | Male | 27 | 29.6 | 91.2 | (60.1-132.6) |
| Female | 4 | 4.1 | nc | (nc-nc) |  | Female | 16 | 26.5 | 60.3 | (34.5-98.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

100

# Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 2.1 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 4 | 7.9 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 2.3 | 262.1 | (95.7-570.5) |  |  |  |  |  |  |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 7.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 3 | 1.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 3.7 | nc | (nc-nc) |  | Male | 17 | 27.9 | 60.9 | (35.5-97.5) |
| Female | 2 | 3.7 | nc | (nc-nc) |  | Female | 19 | 26.6 | 71.5 | (43.0-111.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

101

# Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 4.4 | 136.0 | (49.7-296.0) |  | Male | 5 | 2.9 | 174.7 | (56.3-407.6) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 8 | 15.3 | 52.2 | (22.5-102.8) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 2.1 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 4.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 4.1 | nc | (nc-nc) |  | Female | 4 | 1.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 16.2 | 43.2 | (17.3-89.0) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 8.0 | 124.8 | (59.8-229.6) |  | Male | 55 | 59.3 | 92.8 | (69.9-120.8) |
| Female | 8 | 7.0 | 114.8 | (49.4-226.2) |  | Female | 44 | 50.8 | 86.6 | (62.9-116.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

102

# Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 34 | 35.2 | 96.6 | (66.9-135.0) |  | Male | 18 | 24.0 | 75.0 | (44.4-118.5) |
| Female | 9 | 13.7 | 65.6 | (29.9-124.6) |  | Female | 6 | 21.1 | 28.4 | (10.4-61.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 7.5 | 66.6 | (21.5-155.3) |  | Male | 8 | 6.8 | 118.2 | (50.9-233.0) |
| Female | 3 | 6.5 | nc | (nc-nc) |  | Female | 5 | 5.8 | 85.8 | (27.6-200.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 15 | 21.3 | 70.4 | (39.4-116.1) |
| Female | 135 | 152.5 | 88.5 | (74.2-104.8) |  | Female | 15 | 18.7 | 80.1 | (44.8-132.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 19 | 16.6 | 114.4 | (68.9-178.7) |
| Female | 15 | 5.9 | 255.8 | (143.0-421.9) |  | Female | 6 | 7.7 | 77.5 | (28.3-168.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 42 | 39.7 | 105.7 | (76.2-142.9) |  |  |  |  |  |  |
| Female | 40 | 42.5 | 94.2 | (67.3-128.3) |  | Female | 12 | 13.9 | 86.1 | (44.4-150.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 9.3 | 85.8 | (36.9-169.0) |  | Male | 15 | 12.0 | 125.5 | (70.2-207.0) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 17 | 13.4 | 127.2 | (74.1-203.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 3.7 | nc | (nc-nc) |  | Male | 101 | 122.1 | 82.7 | (67.4-100.5) |
| Female | 5 | 3.1 | 162.5 | (52.4-379.3) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 24 | 19.8 | 120.9 | (77.5-179.9) |  | Male | 16 | 8.3 | 191.8 | (109.6-311.5) |
| Female | 15 | 12.1 | 123.8 | (69.2-204.1) |  | Female | 9 | 5.4 | 168.2 | (76.8-319.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 5.2 | nc | (nc-nc) |  | Male | 5 | 7.0 | 71.0 | (22.9-165.7) |
| Female | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 15.0 | 46.8 | (18.7-96.4) |  | Male | 8 | 10.1 | 79.2 | (34.1-156.0) |
| Female | 14 | 11.6 | 120.2 | (65.7-201.7) |  | Female | 27 | 32.1 | 84.1 | (55.4-122.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 17 | 12.0 | 141.5 | (82.4-226.6) |  |  |  |  |  |  |
| Female | 8 | 4.1 | 193.4 | (83.3-381.2) |  | Female | 28 | 33.6 | 83.2 | (55.3-120.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 86 | 63.2 | 136.1 | (108.8-168.0) |  | Male | 465 | 477.4 | 97.4 | (88.7-106.7) |
| Female | 104 | 70.9 | 146.8 | (119.9-177.8) |  | Female | 515 | 520.6 | 98.9 | (90.6-107.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

103

# Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 26 | 22.0 | 118.1 | (77.2-173.1) |  | Male | 7 | 13.5 | 52.0 | (20.8-107.2) |
| Female | 15 | 8.7 | 171.4 | (95.9-282.8) |  | Female | 13 | 10.8 | 120.7 | (64.2-206.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.6 | nc | (nc-nc) |  | Male | 6 | 4.0 | 149.0 | (54.4-324.2) |
| Female | 5 | 3.3 | 152.5 | (49.1-355.9) |  | Female | 2 | 3.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 9 | 11.9 | 75.4 | (34.4-143.1) |
| Female | 79 | 82.1 | 96.2 | (76.2-119.9) |  | Female | 10 | 11.0 | 91.2 | (43.7-167.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 9.1 | 87.7 | (37.8-172.9) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 23.5 | 72.4 | (42.2-116.0) |  |  |  |  |  |  |
| Female | 26 | 26.4 | 98.4 | (64.3-144.2) |  | Female | 9 | 7.7 | 117.2 | (53.5-222.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.6 | nc | (nc-nc) |  | Male | 6 | 7.3 | 82.3 | (30.1-179.2) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 11 | 8.7 | 127.0 | (63.3-227.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 92 | 72.7 | 126.6 | (102.0-155.2) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 10.9 | 156.5 | (91.1-250.6) |  | Male | 8 | 5.0 | 160.2 | (69.0-315.8) |
| Female | 10 | 6.8 | 146.8 | (70.3-270.0) |  | Female | 4 | 3.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 3.0 | 262.7 | (113.1-517.7) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 3 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 8.3 | 157.3 | (83.7-269.0) |  | Male | 5 | 4.7 | 106.8 | (34.4-249.2) |
| Female | 8 | 6.5 | 122.5 | (52.7-241.3) |  | Female | 17 | 13.5 | 126.3 | (73.5-202.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 6.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 17 | 18.6 | 91.4 | (53.2-146.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 60 | 38.7 | 155.0 | (118.3-199.5) |  | Male | 321 | 276.9 | 115.9 | (103.6-129.3) |
| Female | 54 | 42.7 | 126.4 | (94.9-164.9) |  | Female | 319 | 292.3 | 109.1 | (97.5-121.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

104

# Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 105 | 92.1 | 114.1 | (93.3-138.1) |  | Male | 32 | 59.0 | 54.2 | (37.1-76.5) |
| Female | 34 | 38.4 | 88.6 | (61.4-123.8) |  | Female | 22 | 51.9 | 42.4 | (26.6-64.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 19 | 17.3 | 110.1 | (66.3-172.0) |  | Male | 14 | 17.2 | 81.6 | (44.6-136.9) |
| Female | 11 | 16.1 | 68.3 | (34.0-122.2) |  | Female | 16 | 16.0 | 100.1 | (57.2-162.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 47 | 52.4 | 89.7 | (65.9-119.3) |
| Female | 287 | 379.7 | 75.6 | (67.1-84.9) |  | Female | 60 | 49.7 | 120.7 | (92.1-155.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 43 | 40.5 | 106.2 | (76.9-143.1) |
| Female | 17 | 13.3 | 127.9 | (74.4-204.7) |  | Female | 16 | 20.2 | 79.1 | (45.2-128.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 123 | 100.5 | 122.4 | (101.8-146.1) |  |  |  |  |  |  |
| Female | 131 | 116.9 | 112.0 | (93.7-132.9) |  | Female | 22 | 35.4 | 62.1 | (38.9-94.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 21 | 23.9 | 87.9 | (54.4-134.3) |  | Male | 37 | 30.9 | 119.6 | (84.2-164.9) |
| Female | 5 | 7.3 | 68.8 | (22.2-160.6) |  | Female | 33 | 37.8 | 87.3 | (60.1-122.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 11 | 7.7 | 143.5 | (71.5-256.8) |  | Male | 274 | 314.6 | 87.1 | (77.1-98.0) |
| Female | 6 | 6.9 | 87.1 | (31.8-189.7) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 44 | 48.3 | 91.1 | (66.2-122.3) |  | Male | 39 | 21.3 | 183.2 | (130.2-250.4) |
| Female | 35 | 31.2 | 112.1 | (78.1-155.9) |  | Female | 30 | 14.9 | 201.3 | (135.8-287.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 21 | 13.1 | 159.8 | (98.9-244.3) |  | Male | 17 | 13.4 | 126.5 | (73.6-202.5) |
| Female | 11 | 4.7 | 235.3 | (117.3-421.0) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 35 | 36.8 | 95.1 | (66.2-132.3) |  | Male | 19 | 22.5 | 84.3 | (50.8-131.7) |
| Female | 43 | 30.5 | 140.9 | (102.0-189.9) |  | Female | 82 | 71.0 | 115.6 | (91.9-143.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 29 | 29.9 | 96.9 | (64.9-139.1) |  |  |  |  |  |  |
| Female | 14 | 11.1 | 126.2 | (68.9-211.8) |  | Female | 99 | 85.3 | 116.1 | (94.4-141.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 250 | 163.9 | 152.6 | (134.2-172.7) |  | Male | 1287 | 1202.6 | 107.0 | (101.3-113.0) |
| Female | 212 | 190.7 | 111.2 | (96.7-127.2) |  | Female | 1321 | 1341.5 | 98.5 | (93.2-103.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

105

# Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 58 | 56.8 | 102.1 | (77.5-132.0) |  | Male | 28 | 33.0 | 84.8 | (56.4-122.6) |
| Female | 17 | 20.6 | 82.3 | (47.9-131.8) |  | Female | 33 | 24.3 | 135.8 | (93.4-190.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 15 | 8.2 | 181.9 | (101.7-300.0) |  | Male | 9 | 10.1 | 89.0 | (40.6-169.0) |
| Female | 9 | 7.5 | 120.4 | (54.9-228.5) |  | Female | 9 | 8.6 | 104.8 | (47.8-199.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.7 | nc | (nc-nc) |  | Male | 30 | 28.9 | 103.7 | (69.9-148.0) |
| Female | 215 | 193.0 | 111.4 | (97.0-127.3) |  | Female | 27 | 25.8 | 104.6 | (68.9-152.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 30 | 21.6 | 139.2 | (93.9-198.7) |
| Female | 5 | 5.6 | 88.7 | (28.6-207.0) |  | Female | 7 | 10.5 | 66.9 | (26.8-137.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 59 | 57.7 | 102.2 | (77.8-131.9) |  |  |  |  |  |  |
| Female | 52 | 60.1 | 86.5 | (64.6-113.5) |  | Female | 22 | 18.0 | 122.4 | (76.7-185.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 14.1 | 92.1 | (49.0-157.4) |  | Male | 13 | 18.6 | 70.0 | (37.3-119.8) |
| Female | 6 | 4.0 | 151.5 | (55.3-329.8) |  | Female | 19 | 20.2 | 94.2 | (56.7-147.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 213 | 184.5 | 115.5 | (100.5-132.1) |
| Female | 3 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 27 | 26.2 | 103.0 | (67.9-149.9) |  | Male | 11 | 12.5 | 87.8 | (43.8-157.1) |
| Female | 12 | 16.3 | 73.8 | (38.1-128.9) |  | Female | 3 | 7.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 7.7 | 117.3 | (53.5-222.8) |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 4 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 20.1 | 89.4 | (52.9-141.3) |  | Male | 12 | 10.1 | 118.6 | (61.2-207.2) |
| Female | 9 | 14.8 | 60.6 | (27.7-115.1) |  | Female | 14 | 28.5 | 49.2 | (26.9-82.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 18 | 16.8 | 107.4 | (63.6-169.7) |  |  |  |  |  |  |
| Female | 3 | 6.0 | nc | (nc-nc) |  | Female | 36 | 45.3 | 79.4 | (55.6-110.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 68 | 101.1 | 67.2 | (52.2-85.3) |  | Male | 701 | 690.6 | 101.5 | (94.1-109.3) |
| Female | 112 | 106.1 | 105.6 | (86.9-127.1) |  | Female | 666 | 685.0 | 97.2 | (90.0-104.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

106

# Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 36 | 36.8 | 97.9 | (68.5-135.5) |  | Male | 16 | 24.3 | 65.8 | (37.6-106.9) |
| Female | 15 | 14.4 | 104.1 | (58.2-171.7) |  | Female | 14 | 20.8 | 67.4 | (36.8-113.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 7.4 | 80.7 | (29.5-175.7) |  | Male | 13 | 7.0 | 185.3 | (98.6-316.9) |
| Female | 7 | 6.5 | 106.9 | (42.8-220.3) |  | Female | 8 | 6.1 | 131.9 | (56.8-260.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 19 | 21.7 | 87.5 | (52.7-136.7) |
| Female | 130 | 150.5 | 86.4 | (72.2-102.6) |  | Female | 19 | 19.2 | 99.2 | (59.7-154.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 27 | 17.0 | 158.9 | (104.7-231.2) |
| Female | 9 | 5.4 | 165.2 | (75.4-313.7) |  | Female | 10 | 7.9 | 127.1 | (60.8-233.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 31 | 41.0 | 75.7 | (51.4-107.4) |  |  |  |  |  |  |
| Female | 44 | 44.5 | 98.9 | (71.9-132.8) |  | Female | 12 | 14.0 | 85.5 | (44.1-149.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 9.7 | 112.9 | (56.3-202.1) |  | Male | 12 | 12.4 | 96.6 | (49.8-168.7) |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 9 | 14.2 | 63.4 | (28.9-120.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 3.5 | nc | (nc-nc) |  | Male | 112 | 128.3 | 87.3 | (71.9-105.0) |
| Female | 0 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 22 | 20.1 | 109.4 | (68.5-165.6) |  | Male | 13 | 8.6 | 150.7 | (80.1-257.7) |
| Female | 11 | 12.2 | 90.4 | (45.1-161.8) |  | Female | 6 | 5.6 | 106.4 | (38.8-231.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 5.4 | nc | (nc-nc) |  | Male | 6 | 6.2 | 96.4 | (35.2-209.8) |
| Female | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 15.3 | 98.2 | (54.9-161.9) |  | Male | 4 | 9.8 | nc | (nc-nc) |
| Female | 11 | 12.0 | 92.0 | (45.9-164.7) |  | Female | 23 | 29.8 | 77.2 | (48.9-115.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 12.5 | 79.8 | (38.2-146.8) |  |  |  |  |  |  |
| Female | 3 | 4.3 | nc | (nc-nc) |  | Female | 38 | 33.6 | 113.0 | (79.9-155.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 87 | 66.0 | 131.8 | (105.6-162.6) |  | Male | 485 | 492.8 | 98.4 | (89.8-107.6) |
| Female | 87 | 72.4 | 120.2 | (96.3-148.3) |  | Female | 502 | 524.0 | 95.8 | (87.6-104.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

107

# Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 8 | 14.7 | 54.4 | (23.4-107.3) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 10 | 10.2 | 98.0 | (46.9-180.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

108

# Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 17.7 | 84.8 | (47.4-139.8) |  | Male | 22 | 11.8 | 186.1 | (116.6-281.8) |
| Female | 5 | 6.2 | 80.3 | (25.9-187.4) |  | Female | 14 | 9.3 | 150.7 | (82.3-252.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.5 | 143.6 | (46.3-335.1) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 5 | 2.9 | 173.7 | (56.0-405.3) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 13 | 10.4 | 124.9 | (66.4-213.6) |
| Female | 81 | 72.5 | 111.8 | (88.8-138.9) |  | Female | 6 | 8.6 | 70.1 | (25.6-152.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 8.6 | 81.5 | (32.6-167.9) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 2 | 3.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 20.1 | 94.7 | (57.0-147.9) |  |  |  |  |  |  |
| Female | 16 | 19.1 | 83.7 | (47.8-135.9) |  | Female | 10 | 6.5 | 153.7 | (73.6-282.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 4.9 | nc | (nc-nc) |  | Male | 5 | 6.1 | 81.8 | (26.4-190.8) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 5 | 6.0 | 83.3 | (26.8-194.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 70 | 66.4 | 105.5 | (82.2-133.3) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 10.1 | 79.1 | (34.1-156.0) |  | Male | 6 | 4.2 | 142.4 | (52.0-309.9) |
| Female | 8 | 5.6 | 141.7 | (61.0-279.3) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.7 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 7.1 | 112.3 | (48.4-221.4) |  | Male | 5 | 4.7 | 106.3 | (34.3-248.1) |
| Female | 7 | 5.1 | 137.9 | (55.2-284.1) |  | Female | 20 | 13.7 | 145.5 | (88.8-224.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 6.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 18 | 16.4 | 109.9 | (65.1-173.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 30 | 32.7 | 91.8 | (61.9-131.0) |  | Male | 251 | 243.2 | 103.2 | (90.8-116.8) |
| Female | 32 | 33.3 | 96.0 | (65.7-135.6) |  | Female | 257 | 240.1 | 107.1 | (94.4-121.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

109

# Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 50 | 68.4 | 73.1 | (54.3-96.4) |  | Male | 41 | 44.8 | 91.5 | (65.6-124.1) |
| Female | 29 | 26.5 | 109.3 | (73.2-156.9) |  | Female | 29 | 37.8 | 76.7 | (51.4-110.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 14 | 13.3 | 105.5 | (57.6-177.1) |  | Male | 17 | 12.9 | 131.6 | (76.6-210.7) |
| Female | 4 | 11.7 | nc | (nc-nc) |  | Female | 14 | 11.1 | 125.6 | (68.6-210.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 38 | 39.7 | 95.7 | (67.7-131.3) |
| Female | 282 | 276.5 | 102.0 | (90.4-114.6) |  | Female | 36 | 35.1 | 102.6 | (71.8-142.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 29 | 30.9 | 93.8 | (62.8-134.7) |
| Female | 15 | 10.1 | 148.7 | (83.2-245.3) |  | Female | 7 | 14.4 | 48.6 | (19.5-100.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 71 | 75.5 | 94.0 | (73.4-118.6) |  |  |  |  |  |  |
| Female | 88 | 82.0 | 107.4 | (86.1-132.3) |  | Female | 26 | 25.6 | 101.8 | (66.4-149.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 15 | 17.9 | 83.7 | (46.8-138.1) |  | Male | 29 | 23.1 | 125.7 | (84.2-180.5) |
| Female | 8 | 5.0 | 159.1 | (68.5-313.6) |  | Female | 26 | 26.2 | 99.4 | (64.9-145.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 6.0 | 83.1 | (26.8-193.9) |  | Male | 221 | 235.1 | 94.0 | (82.0-107.3) |
| Female | 7 | 5.1 | 136.6 | (54.7-281.4) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 44 | 36.9 | 119.3 | (86.7-160.1) |  | Male | 19 | 16.0 | 119.0 | (71.6-185.9) |
| Female | 16 | 22.2 | 72.0 | (41.1-116.9) |  | Female | 15 | 10.4 | 143.9 | (80.5-237.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 9.9 | 50.6 | (16.3-118.0) |  | Male | 8 | 10.9 | 73.2 | (31.5-144.3) |
| Female | 3 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 29 | 27.8 | 104.5 | (69.9-150.0) |  | Male | 20 | 17.7 | 113.1 | (69.0-174.6) |
| Female | 22 | 21.6 | 101.7 | (63.7-154.0) |  | Female | 52 | 54.1 | 96.1 | (71.7-126.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 24 | 22.7 | 105.8 | (67.8-157.4) |  |  |  |  |  |  |
| Female | 10 | 7.8 | 128.5 | (61.5-236.3) |  | Female | 62 | 61.6 | 100.7 | (77.2-129.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 106 | 122.1 | 86.8 | (71.1-105.0) |  | Male | 852 | 904.6 | 94.2 | (88.0-100.7) |
| Female | 134 | 132.3 | 101.3 | (84.9-120.0) |  | Female | 989 | 959.6 | 103.1 | (96.7-109.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

110

# Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 28 | 24.9 | 112.5 | (74.7-162.5) |  | Male | 17 | 17.8 | 95.6 | (55.6-153.0) |
| Female | 9 | 9.0 | 99.7 | (45.5-189.4) |  | Female | 17 | 15.1 | 112.4 | (65.4-180.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 5.8 | nc | (nc-nc) |  | Male | 9 | 5.1 | 178.0 | (81.2-338.0) |
| Female | 4 | 4.8 | nc | (nc-nc) |  | Female | 3 | 4.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 8 | 15.8 | 50.5 | (21.7-99.5) |
| Female | 120 | 116.9 | 102.6 | (85.1-122.7) |  | Female | 14 | 13.0 | 107.4 | (58.7-180.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 13.4 | 97.0 | (51.6-166.0) |
| Female | 4 | 4.5 | nc | (nc-nc) |  | Female | 1 | 5.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 32 | 30.0 | 106.7 | (72.9-150.6) |  |  |  |  |  |  |
| Female | 32 | 28.9 | 110.6 | (75.6-156.1) |  | Female | 8 | 10.3 | 77.6 | (33.4-152.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 7.1 | 126.9 | (57.9-241.0) |  | Male | 13 | 8.8 | 148.0 | (78.7-253.0) |
| Female | 3 | 1.7 | nc | (nc-nc) |  | Female | 6 | 8.7 | 68.8 | (25.1-149.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 106 | 95.2 | 111.4 | (91.2-134.7) |
| Female | 6 | 2.1 | 290.6 | (106.1-632.4) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 15.5 | 83.8 | (44.6-143.4) |  | Male | 7 | 6.2 | 113.5 | (45.5-233.9) |
| Female | 12 | 8.8 | 137.0 | (70.7-239.4) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 4.0 | 225.8 | (103.0-428.7) |  | Male | 5 | 4.4 | 113.2 | (36.5-264.1) |
| Female | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 11.0 | 100.2 | (50.0-179.3) |  | Male | 12 | 7.8 | 153.1 | (79.0-267.5) |
| Female | 5 | 8.0 | 62.3 | (20.1-145.3) |  | Female | 30 | 24.5 | 122.5 | (82.6-174.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 9.5 | 115.9 | (57.8-207.4) |  |  |  |  |  |  |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 29 | 25.6 | 113.2 | (75.8-162.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 35 | 45.8 | 76.4 | (53.2-106.2) |  | Male | 369 | 358.4 | 103.0 | (92.7-114.0) |
| Female | 40 | 48.1 | 83.1 | (59.3-113.1) |  | Female | 377 | 375.7 | 100.4 | (90.5-111.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

111